To include your compound in the COVID-19 Resource Center, submit it here.

Latest Spinraza data boost Biogen shares

Biogen Inc. (NASDAQ:BIIB) gained $11.82 to $326.74 on Thursday after reporting data from two trials of spinal muscular atrophy (SMA) drug Spinraza nusinersen. The company said data from the Phase III ENDEAR trial showed that

Read the full 353 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE